BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32174692)

  • 21. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
    Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
    PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.
    Kang KW; Lee BH; Jeon MJ; Yu ES; Sik Kim D; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
    Ther Adv Hematol; 2020; 11():2040620720966882. PubMed ID: 35154623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
    White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
    J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience.
    Soyer N; Kiper Ünal HD; Vural F; Şahin F; Töbü M; Dönmez A; Tombuloğlu M; Arda B; Saydam G
    Turk J Med Sci; 2017 Nov; 47(5):1535-1542. PubMed ID: 29151329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
    Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
    Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
    Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
    Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
    Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
    Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections.
    Hsu A; Matera R; Vieira K; Reagan JL; Farmakiotis D
    Support Care Cancer; 2021 Feb; 29(2):707-712. PubMed ID: 32435969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
    Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis.
    Silva WFD; Mendes FR; Melo RDCB; Velloso EDRP; Rocha V; Rego EM
    J Mycol Med; 2023 Nov; 33(4):101434. PubMed ID: 37683564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
    Strand AM; Alexander BD; Sarpong E; Wong JR; Engemann A; Rizzieri D; Wu Y; Johnson MD
    Mycoses; 2022 Nov; 65(11):1050-1060. PubMed ID: 35816393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
    Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
    Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years.
    Avcu G; Karadas N; Goktepe SO; Bal ZS; Metin DY; Polat SH; Aydinok Y; Karapinar DY
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):392-397. PubMed ID: 37526370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
    Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
    Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience.
    Atoui A; Omeirat N; Fakhreddine O; El Alam R; Kanafani Z; Abou Dalle I; Bazarbachi A; El-Cheikh J; Kanj SS
    J Fungi (Basel); 2021 Oct; 7(11):. PubMed ID: 34829213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.